Market Cap | 181.97B | P/E | 27.08 | EPS this Y | 6.20% | Ern Qtrly Grth | -91.00% |
Income | 6.95B | Forward P/E | 12.21 | EPS next Y | 7.80% | 50D Avg Chg | -5.00% |
Sales | 51.83B | PEG | 3.02 | EPS past 5Y | 5.36% | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 3.09 | EPS next 5Y | 4.50% | 52W High Chg | -9.00% |
Recommedations | 2.20 | Quick Ratio | 0.95 | Shares Outstanding | 2.12B | 52W Low Chg | 16.00% |
Insider Own | 0.01% | ROA | 4.61% | Shares Float | 2.05B | Beta | - |
Inst Own | 8.63% | ROE | 10.93% | Shares Shorted/Prior | 5.32M/5.36M | Price | 85.85 |
Gross Margin | 70.12% | Profit Margin | 13.42% | Avg. Volume | 2,025,475 | Target Price | 104.25 |
Oper. Margin | 17.75% | Earnings Date | - | Volume | 3,852,437 | Change | -0.29% |
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Wolfe Research | Peer Perform | May 9, 22 |
Exane BNP Paribas | Neutral | Dec 6, 21 |
Bryan Garnier | Neutral | Dec 3, 21 |
Deutsche Bank | Sell | Sep 20, 21 |
Argus Research | Hold | Mar 10, 21 |
Cowen & Co. | Market Perform | Feb 1, 21 |
Deutsche Bank | Buy | Jan 15, 21 |
Morgan Stanley | Overweight | Sep 1, 20 |
Guggenheim Securities | Neutral | Feb 25, 20 |